Aurobindo Pharma gets USFDA’s nod for Felodipine extended-release tablets

18 Jan 2013 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.

Felodipine extended-release tablets USP 2.5mg, 5mg, and 10mg is the generic equivalent of AstraZeneca’s Plendil Extended-release Tablets, 2.5mg, 5mg and 10mg and indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

The annual sale of the product is approximately $64 million for the twelve months ending March 2012 according to IMS. Aurobindo now has a total of 172 ANDA approvals (147 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×